Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study
用户gqaUGeP9LdCw
2个月前
60
10
已完结
1. 系统已在2025-07-25 14:43:25对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.lungcan.2025.108447
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0169500225000686
其他信息:
出版社: Elsevier BV
作者: Kenji Morimoto; Tadaaki Yamada; Naoki Furuya; Hisashi Tanaka; Akihiro Yoshimura; Tomohiro Oba; Makoto Hibino; Takahito Fukuda; Yasuhiro Goto; Akira Nakao; Shinsuke Ogusu; Yuta Okazaki; Taishi Harada; Takayo Ota; Ken Masubuchi; Koji Mikami; Tae Hata; Shoki Matsumoto; Ryoichi Honda; Koji Date; Yusuke Chihara; Koichi Takayama
